Leading health agency says no to HRT
A leading US health agency is standing firm on its recommendation against the use of hormone replacement therapy (HRT) in postmenopausal women.
In a review of its 2012 recommendations, the US Preventive Services Task Force (USPSTF) has again concluded that the evidence does not support a role for HRT for preventing fractures and other chronic conditions.
While oral or transdermal HRT may have a place for managing vasomotor symptoms, the agency says it has “no net benefit” for the primary prevention of chronic diseases.
The review of evidence from 18 controlled trials found that combined oestrogen and progestin therapy reduces the risk of diabetes, fractures, and colorectal cancer, but increases the risk for invasive breast cancer, coronary heart disease, dementia, stroke and VTE.
“Although the use